Study suggests lung cancer patients with HER2 mutations may benefit from anti-HER2 dr

[News]

New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced non-small cell lung cancer (NSCLC) harboring specific HER2 protein mutations.

More... (http://www.news-medical.net/news/20130423/Study-suggests-lung-cancer-patients-with-HER2-mutations-may-benefit-from-anti-HER2-drugs.aspx)